1. Scrip
  2. >>Business
  3. >>Strategy

Beyond Belviq: Reinventing Arena To Focus On Phase II Candidates

 
• By Mike Ward

Dr. Amit Munshi, new CEO of Arena Pharmaceuticals, has already made several changes in the company’s focus and direction as it reduces its commitment to Belviq. He talked to Mike Ward about progress to date.

Video interview
Arena's CEO Amit Munshi talks to Scrip at Biotech Showcase

In the six months after joining Arena Pharmaceuticals Inc. as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq (lorcaserin), which it has partnered with Eisai Co. Ltd.; spinning out the discovery research activities into a new company, Beacon Discovery; and prioritizing three Phase II programs with readouts in 2017.

Munshi updates Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, on the company’s progress to date,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 
• By Anju Ghangurde

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

More from Business

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 
• By Anju Ghangurde

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.